tipifarnib has been researched along with Sepsis in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Hirai, S; Hisaka, S; Ichinose, F; Kaneki, M; Shirozu, K; Tanaka, T | 1 |
1 other study(ies) available for tipifarnib and Sepsis
Article | Year |
---|---|
Farnesyltransferase inhibitor, tipifarnib, prevents galactosamine/lipopolysaccharide-induced acute liver failure.
Topics: Animals; Caspase 3; Cell Survival; Cytokines; Endotoxemia; Enzyme Inhibitors; Farnesyltranstransferase; Galactosamine; Gene Expression Regulation; Hepatocytes; Inflammation; Interleukin-6; Lipids; Lipopolysaccharides; Liver; Liver Failure, Acute; Male; Mice; Mice, Inbred C57BL; Quinolones; Sepsis; Tumor Necrosis Factor-alpha | 2014 |